



30 August 2024

Company Announcements Office
Australian Securities Exchange

Agreement with C14 Consulting Group

Consistent with the Company's strategic initiatives on commercialisation, Vectus has appointed C14 Consulting Group, LLC in an exclusive role to lead and manage the programme of potential licencing, joint venture or both of Vectus' portfolio of patented small therapeutic molecules, including the human lead VB0004.

Vectus' drug library focuses on a range of anti-fibrotic applications aimed at cardio vascular disease, a significant unmet need. Specifically, VB0004, A32, A79 target reversal of disease in the heart, lung, kidney and liver. VB0004 has successfully undergone human Phase Ia trials and more recently Phase Ib human trials, with no adverse events recorded.

Based in the USA, C14 is a highly regarded consultancy with a global capability. Led by Martina Molsbergen (Chief Executive Officer), the company has an enviable track record of securing licence agreements, joint ventures and commercialisation of pharmaceutical patented assets with all levels of pharma from large scale to biotech companies that specialise in orphan and targeted applications. C14 will now be managing existing discussions with, and expanding the outreach to, potential pharmaceutical partners. C14 has demonstrated that it has long standing relationships with a broad cross section of pharmaceutical companies and a detailed knowledge of the indications and market segments on which each of these companies are currently focusing.

Providing for a management fee and an outcome-based success component, the agreement aligns the interests of the parties achieving one or more commercial outcomes. C14 business model is predicated on a broad analysis of the client's technologies and typically engages with a client when there is a belief in the potential of the technology to be commercialised.

Ms Martina Molsbergen, Chief Executive Officer of the licencing firm in the USA, C14 Consulting Group commented: "C14 has a long track record in helping companies such as Vectus to advance towards the commercialisation of novel therapies. From our preliminary review of VB0004 and associated drug library, we have realised the compelling research that has been conducted thus far and the potential to be taken up by pharma in the exciting space of fibrosis remediation."

Dr Ron Shnier, Vectus Non-Executive Chairman said: "We are pleased to be partnering with C14, one of the world's leading consultancies in pharmaceutical transactions. As previously reported, Vectus is concentrating its activities on achieving licencing or partnerships with its patented anti-fibrotic portfolio."

Vectus Biosystems Limited

Dr Ron Shnier
Chairman

This announcement was authorised by the Company's Board of Directors.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

Ground Floor, Unit 5, 26-34 Dunning Avenue, Rosebery NSW 2018 Australia
Telephone: +61 2 8344 1300, Facsimile: +61 2 9697 0944
Email: info@vectusbiosystems.com.au
Website: www.vectusbiosystems.com.au

Martina Molsbergen

Martina Molsbergen has more than 33 years of Business Development and Marketing experience. She is currently the Chief Executive Officer of C14 Consulting, a business development advisory firm serving the life sciences community since 2009. Previously, Ms Molsbergen held several leadership roles in business development including most recently as Interim Chief Business Officer of Pyxis Oncology (NASDAQ:PYXS). She has served as Senior Vice President for several biotechs like AbSci, Sorrento Therapeutics, Selexis SA, Oxford Biotherapeutics, Immunome, NewBiologix, and others. She has served on the board of directors of Bio-Path Holdings Inc (NASDAQ:BPTH), OCMS Bio and Score Pharma. She served as vice president of business development of Crucell Holland BV, where she managed the company's joint venture with DSM Biologics; vice president of business development of Biowa, Inc., where she negotiated more than 15 deals valued at over \$2.5 billion; vice president of business development of Zetiq Technologies Ltd. and vice president of pharmaceutical development services & business development of Patheon Inc. Her career has earned her an expertise in business development and marketing in areas including biotherapeutics, immunotherapies and regenerative medicine, especially with cutting edge tools, technologies and products. Ms Molsbergen holds a Bachelor of Science in chemical engineering from Drexel University.